Natixis Advisors
MRNA icon

Natixis Advisors’s Moderna MRNA Stock Holding History

Natixis Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.02M Buy
28,886
+15,396
+114% +$797K ﹤0.01% 1233
2026
Q1 		$685K Buy
+13,490
New +$629K ﹤0.01% 1463
2025
Q2 		– Sell
-17,761
Closed -$504K – 1665
2025
Q1 		$504K Buy
17,761
+7,356
+71% +$261K ﹤0.01% 1454
2024
Q4 		$433K Sell
10,405
-1,169
-10% -$55.9K ﹤0.01% 1501
2024
Q3 		$773K Sell
11,574
-58,936
-84% -$5.41M ﹤0.01% 1364
2024
Q2 		$8.37M Buy
70,510
+40,021
+131% +$5.06M 0.02% 658
2024
Q1 		$3.25M Buy
30,489
+5,877
+24% +$592K 0.01% 901
2023
Q4 		$2.45M Buy
24,612
+4,688
+24% +$394K 0.01% 944
2023
Q3 		$2.06M Buy
19,924
+3,310
+20% +$369K 0.01% 980
2023
Q2 		$2.02M Sell
16,614
-12,709
-43% -$1.7M 0.01% 958
2023
Q1 		$4.5M Buy
29,323
+573
+2% +$94.5K 0.02% 717
2022
Q4 		$5.16M Buy
28,750
+3,313
+13% +$542K 0.02% 675
2022
Q3 		$3.01M Buy
25,437
+13,586
+115% +$2.06M 0.01% 768
2022
Q2 		$1.69M Sell
11,851
-1,586
-12% -$227K 0.01% 960
2022
Q1 		$2.31M Buy
13,437
+3,178
+31% +$535K 0.01% 920
2021
Q4 		$2.61M Sell
10,259
-67,297
-87% -$19.7M 0.01% 876
2021
Q3 		$29.8M Sell
77,556
-145,991
-65% -$53.8M 0.12% 175
2021
Q2 		$52.5M Buy
+223,547
New +$40M 0.25% 95

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Natixis Advisors's MRNA Position: Q2 2026 in Review

Natixis Advisors increased its Moderna (MRNA) stake by 114% in Q2 2026, buying an estimated $797K and bringing the position to 28,886 shares worth $2.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1233.

Natixis Advisors first reported a position in MRNA in Q2 2021 and has held it in 18 quarters since. The position peaked at $52.5M in Q2 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Natixis Advisors held 28,886 shares of Moderna worth $2.02M as of Q2 2026.
  • Natixis Advisors bought 15,396 Moderna shares in Q2 2026, an estimated $797K.
  • Moderna made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #1233 holding.
  • Natixis Advisors first reported a position in Moderna in Q2 2021 and has held it in 18 quarters since.
  • Natixis Advisors's Moderna position peaked at $52.5M in Q2 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.